A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation

Kim,Kang-Mi; Song,Myung-Ha; Kim,Min-Ju; Daudi,Sayeema; Miliotto,Anthony; Old,Lloyd; Odunsi,Kunle; Lee,Sang-Yull

doi:10.3892/ijo.2012.1508

A novel cancer/testis antigen KP-OVA-52 identified by SEREX in human ovarian cancer is regulated by DNA methylation

Authors:
- Kang-Mi Kim
- Myung-Ha Song
- Min-Ju Kim
- Sayeema Daudi
- Anthony Miliotto
- Lloyd Old
- Kunle Odunsi
- Sang-Yull Lee
View Affiliations

Affiliations: Department of Microbiology and Immunology, School of Medicine, Pusan National University, Yangsan-si, Gyeongsangnam-do 626-770, Republic of Korea, Department of Biochemistry, School of Medicine, Pusan National University, Yangsan-si, Gyeongsangnam-do 626-770, Republic of Korea, Department of Gynecologic Oncology and Center for Immunotherapy Roswell Park Cancer Institute, New York, NY 142634, USA, Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Published online on: June 6, 2012 https://doi.org/10.3892/ijo.2012.1508
Pages: 1139-1147

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SEREX has proven to be a powerful method that takes advantage of the presence of spontaneous humoral immune response in some cancer patients. In this study, immunoscreening of normal testis and two ovarian cancer cell line cDNA expression libraries with sera from ovarian cancer patients led to the isolation of 75 independent antigens, designated KP-OVA-1 through KP-OVA-75. Of these, RT-PCR showed KP-OVA-52 to be expressed strongly in normal testis, in ovarian cancer cell lines (3/9) and in ovarian cancer tissues (1/17). The expression of KP-OVA-52 in cancer cells is also induced by the demethylating agent 5‑aza‑2'‑deoxycytidine (ADC). To test immunogenicity, we used the Serum Antibody Detection Assay (SADA) to analyze anti-IgG antibodies against the 75 antigens that were initially isolated by SEREX. Four of the 75 antigens (KP‑OVA‑25, KP‑OVA‑35, KP‑OVA‑68 and KP‑OVA‑73) reacted exclusively with sera from cancer patients. However, KP‑OVA‑52 reacted with 1 of 20 ovarian cancer sera. These data suggest that the KP-OVA-52 can be considered a novel CT antigen that is regulated by DNA methylation.

View Figures

View References

1.	Ovarian cancer in Australia: An overview, 2010. Australian Institute of Health and Welfare and National Breast and Ovarian Cancer Centre; Canberra: 2010
2.	Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG and Edwards BK: SEER Cancer Statistics Review 1975–2007. National Cancer Institute; Bethesda, MD: 2011
3.	Hennessy BT, Coleman RL and Markman M: Ovarian cancer. Lancet. 374:1371–1382. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Jaras K and Anderson K: Autoantibodies in cancer: prognostic biomarkers and immune activation. Expert Rev Proteomics. 8:577–589. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I and Pfreundschuh M: Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 92:11810–11813. 1995. View Article : Google Scholar : PubMed/NCBI
6.	Obata Y, Takahashi T, Sakamoto J, Tamaki H, Tominaga S, Hamajima N, Chen YT and Old LJ: SEREX analysis of gastric cancer antigens. Cancer Chemother Pharmacol. 46(Suppl): S37–S42. 2000. View Article : Google Scholar
7.	Song MH, Ha JC, Lee SM, Park YM and Lee SY: Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem Biophys Res Commun. 408:195–201. 2011. View Article : Google Scholar : PubMed/NCBI
8.	Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A and Old LJ: Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA. 95:6919–6923. 1998. View Article : Google Scholar : PubMed/NCBI
9.	Jager D, Stockert E, Scanlan MJ, Gure AO, Jager E, Knuth A, Old LJ and Chen YT: Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res. 59:6197–6204. 1999.PubMed/NCBI
10.	Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT and Old LJ: Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer. 83:456–464. 1999. View Article : Google Scholar : PubMed/NCBI
11.	Lee SY, Williamson B, Caballero OL, Chen YT, Scanlan MJ, Ritter G, Jongeneel CV, Simpson AJ and Old LJ: Identification of the gonad-specific anion transporter SLCO6A1 as a cancer/testis (CT) antigen expressed in human lung cancer. Cancer Immun. 4:132004.PubMed/NCBI
12.	Chen G, Zhang W, Cao X, Li F, Liu X and Yao L: Serological identification of immunogenic antigens in acute monocytic leukemia. Leuk Res. 29:503–509. 2005. View Article : Google Scholar : PubMed/NCBI
13.	Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M and Old LJ: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
14.	Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jager D, Chen YT, Mackay A, O’Hare MJ and Old LJ: Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun. 1:42001.PubMed/NCBI
15.	Jager D, Stockert E, Gure AO, Scanlan MJ, Karbach J, Jager E, Knuth A, Old LJ and Chen YT: Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 61:2055–2061. 2001.PubMed/NCBI
16.	Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 188:22–32. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, Chen YT, Old LJ and Scanlan MJ: Immunomic analysis of human sarcoma. Proc Natl Acad Sci USA. 100:2651–2656. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Simpson AJ, Caballero OL, Jungbluth A, Chen YT and Old LJ: Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 5:615–625. 2005. View Article : Google Scholar : PubMed/NCBI
19.	Scanlan MJ, Simpson AJ and Old LJ: The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 4:12004.PubMed/NCBI
20.	Caballero OL and Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci. 100:2014–2021. 2009. View Article : Google Scholar : PubMed/NCBI
21.	Stone B, Schummer M, Paley PJ, Thompson L, Stewart J, Ford M, Crawford M, Urban N, O’Briant K and Nelson BH: Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q. Int J Cancer. 104:73–84. 2003. View Article : Google Scholar : PubMed/NCBI
22.	Luo LY, Herrera I, Soosaipillai A and Diamandis EP: Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br J Cancer. 87:339–343. 2002. View Article : Google Scholar : PubMed/NCBI
23.	Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, Nolen BM and Gorelik E: Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol. 102:244–251. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Jin S, Wang Y, Zhang Y, Zhang HZ, Wang SJ, Tang JQ, Chen HJ and Ge HL: Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity. Cancer Sci. 99:1670–1678. 2008. View Article : Google Scholar
25.	Naora H, Montz FJ, Chai CY and Roden RB: Aberrant expression of homeobox gene HOXA7 is associated with mullerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc Natl Acad Sci USA. 98:15209–15214. 2001. View Article : Google Scholar : PubMed/NCBI
26.	Naora H, Yang YQ, Montz FJ, Seidman JD, Kurman RJ and Roden RB: A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc Natl Acad Sci USA. 98:4060–4065. 2001. View Article : Google Scholar : PubMed/NCBI
27.	The Academy of Cancer Immunology and the Ludwig Institute for Cancer Research: Cancer Immunome Database. Avaible online: http://ludwig-sun5.unil.ch/CancerImmunomeDB, 1997.
28.	Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Lienard D, Guillaume P, Romero P, Cerottini JC and Rimoldi D: Frequent cytolytic T-cell responses to peptide MAGE-A10(254–262) in melanoma. Cancer Res. 61:509–512. 2001.PubMed/NCBI
29.	Kikuchi N, Horiuchi A, Osada R, Imai T, Wang C, Chen X and Konishi I: Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: an important autocrine/paracrine factor in tumor progression. Cancer Sci. 97:1061–1069. 2006. View Article : Google Scholar
30.	Lin J, Lin L, Thomas DG, Greenson JK, Giordano TJ, Robinson GS, Barve RA, Weishaar FA, Taylor JM, Orringer MB and Beer DG: Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants. Clin Cancer Res. 10:5708–5716. 2004. View Article : Google Scholar : PubMed/NCBI
31.	Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M and Spagnoli GC: Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer. 120:337–343. 2007. View Article : Google Scholar : PubMed/NCBI
32.	Sharma P, Shen Y, Wen S, Bajorin DF, Reuter VE, Old LJ and Jungbluth AA: Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res. 12:5442–5447. 2006. View Article : Google Scholar : PubMed/NCBI
33.	Figueiredo DL, Mamede RC, Proto-Siqueira R, Neder L, Silva WA Jr and Zago MA: Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck. 28:614–619. 2006. View Article : Google Scholar : PubMed/NCBI
34.	Shirley CR, Hayashi S, Mounsey S, Yanagimachi R and Meistrich ML: Abnormalities and reduced reproductive potential of sperm from Tnp1- and Tnp2-null double mutant mice. Biol Reprod. 71:1220–1229. 2004. View Article : Google Scholar : PubMed/NCBI
35.	Park JH, Song MH, Lee CH, Lee MK, Park YM, Old L and Lee SY: Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation. Biotechnol Lett. 33:1085–1091. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Adair SJ and Hogan KT: Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol Immunother. 58:589–601. 2009.